Transfusion-acquired human immunodeficiency virus infection among immunocompromised persons.
Transmission of the human immunodeficiency virus (HIV) was studied in a group of patients with cancer who received transfusion of blood components harvested from a single, asymptomatic, seropositive donor. Of ten living recipients, nine had antibodies to the virus in fresh or cryopreserved sera at a median of 384 days (range, 237 to 686) after transfusion. In three patients, an enzyme-linked immunosorbent assay was negative at the same time that Western blot and radioimmunoprecipitation techniques showed seropositivity. Cultures for HIV obtained at a median of 615 days (range, 322 to 714) after transfusion were positive in seven of nine seropositive recipients. Six seropositive recipients have developed immunologic and clinical sequelae of HIV infection at a median of 286 days (range, 56 to 745) after transfusion. The sera of the two patients without clinical sequelae neutralized HIV in an in-vitro assay, whereas the seven other seropositive patients lacked such neutralizing antibodies. Our study characterizes the clinical, serologic, virologic, and immunologic manifestations of HIV infection in immunocompromised persons.
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000635:transmission*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D017977:Deltaretrovirus / Q000276:immunology; D005260:Female; D015483:HIV Antibodies; D006801:Humans; D007108:Immune Tolerance; D007223:Infant; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology; D012192:Retroviridae Infections / Q000276:immunology / Q000635:transmission*; D013029:Space-Time Clustering; D065227:Transfusion Reaction
D000914:Antibodies, Viral; D015483:HIV Antibodies